TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15704509

Group type: EXPERIMENTAL
Intervention: Home training with additional physical therapy
Number of subjects: 54

Group type: COMPARATOR
Intervention: Home training without additional physical therapy
Number of subjects: 54
Study: 12100642

Group type: EXPERIMENTAL
Intervention: Group V (visual stimuli) - soundless video display of natural scenery during tourniquet inflation
Number of subjects: 46

Group type: COMPARATOR
Intervention: Group B (control) - static blank screen during tourniquet inflation
Number of subjects: 46
Study: 10546865

Group type: EXPERIMENTAL
Intervention: Genital Ulcer Disease (GUD)
Number of subjects: 8089

Group type: EXPERIMENTAL
Intervention: Discharge/Dysuria in males
Number of subjects: 8089

Group type: EXPERIMENTAL
Intervention: Any of the three STD symptoms
Number of subjects: 8089

Group type: EXPERIMENTAL
Intervention: GUD
Number of subjects: 8089

Group type: EXPERIMENTAL
Intervention: STD symptoms in HIV-positive persons
Number of subjects: 8089
Study: 9060344

Group type: EXPERIMENTAL
Intervention: Fall prevention program; Details: Not specified
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Small group education
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fall prevention program with examples of safety devices
Number of subjects: 0
Study: 2005707

Group type: EXPERIMENTAL
Intervention: Oxybutynin
Number of subjects: 154

Group type: COMPARATOR
Intervention: Propantheline
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study: 6386033

Group type: EXPERIMENTAL
Intervention: Zinc oxide treatment (400 micrograms ZnO/cm2)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo treatment (identical compress without zinc oxide)
Number of subjects: 37
Study: 30542749

Group type: EXPERIMENTAL
Intervention: Aspiration sclerotherapy
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 32
Study: 29610765

Group type: EXPERIMENTAL
Intervention: Test implant (modified design intended to increase primary stability)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control implant (standard design)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Both test and control implants
Number of subjects: 33
Study: 26854741

Group type: EXPERIMENTAL
Intervention: Motor imagery (MI) training
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Physical practice (PP) training
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (previous work)
Number of subjects: 60
Study: 25482871

Group type: EXPERIMENTAL
Intervention: Dupilumab 150 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22740508

Group type: EXPERIMENTAL
Intervention: Pentraxin-3 (PTX3) levels measured at randomization and after 3 months
Number of subjects: 2680

Group type: COMPARATOR
Intervention: Rosuvastatin
Number of subjects: 2680
Study: 20435966

Group type: EXPERIMENTAL
Intervention: Transference-focused psychotherapy
Number of subjects: 104

Group type: COMPARATOR
Intervention: Treatment by experienced community psychotherapists
Number of subjects: 104
Study: 18378545

Group type: EXPERIMENTAL
Intervention: Oral glutamine (30 g/day)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 52
Study: 16167225

Group type: EXPERIMENTAL
Intervention: Esophagogastric anastomosis with mucosal valve (Group A, 175 cases)
Number of subjects: 464

Group type: COMPARATOR
Intervention: Mechanical stapler (Group B, 151 cases)
Number of subjects: 464

Group type: COMPARATOR
Intervention: One layer anastomosis with handcraft suture (Group C, 138 cases)
Number of subjects: 464
Study: 12435654

Group type: EXPERIMENTAL
Intervention: Biomechanical orthoses with army boots
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Soft biomechanical orthoses with army boots
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Semirigid biomechanical orthoses with army boots
Number of subjects: 9

Group type: COMPARATOR
Intervention: Biomechanical orthoses with running shoes
Number of subjects: 9
Study: 10551383

Group type: EXPERIMENTAL
Intervention: Interferon-alpha treatment
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Disappearance of HCV RNA from serum at week 4
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Delta sIL-2R
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Disappearance of HCV RNA and delta sIL-2R
Number of subjects: 78
Study: 7599241

Group type: EXPERIMENTAL
Intervention: Orthopedic rehabilitation
Number of subjects: 371

Group type: COMPARATOR
Intervention: Geriatric rehabilitation
Number of subjects: 371
Study: 2217831

Group type: EXPERIMENTAL
Intervention: lipo-PGI2 (2 micrograms daily for one week)
Number of subjects: 17

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: lipo-PGI2
Number of subjects: 17
Study: 649242

Group type: EXPERIMENTAL
Intervention: Acetylsalicyclic acid
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Noramidopyrinium methane sulfonate sodium
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Pentazocin
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Codeine phosphate
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 31434813

Group type: EXPERIMENTAL
Intervention: Unreliable information sources (Internet, TV, radio, word of mouth)
Number of subjects: 2130

Group type: COMPARATOR
Intervention: Reliable information sources (municipal public relations, major media)
Number of subjects: 2130
Study: 28727231

Group type: EXPERIMENTAL
Intervention: Nulliparous women
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Offspring of nulliparous women
Number of subjects: 72
Study: 24471418

Group type: EXPERIMENTAL
Intervention: Self-affirmation condition
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 125
Study: 23508376

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) using green 532 nm diodes
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 68
Study: 21634310

Group type: EXPERIMENTAL
Intervention: Fitness for Life (FFL) program
Number of subjects: 156

Group type: COMPARATOR
Intervention: Traditional high-intensity fitness (TRAD) program
Number of subjects: 156
Study: 19621732

Group type: EXPERIMENTAL
Intervention: Triple-drug Hp eradication therapy (lansoprazole 30 mg bid, amoxicillin 1000 mg bid, clarithromycin 500 mg bid) for 2 weeks
Number of subjects: 44
Study: 17060216

Group type: EXPERIMENTAL
Intervention: Bivariate log-normal survival models
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repeat randomization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Observational study approach
Number of subjects: 0
Study: 15580808

Group type: EXPERIMENTAL
Intervention: Dietary modification (consuming one additional citrus fruit after lunch)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Nutrition education (teaching the mothers proper eating patterns based on the food pyramid)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control
Number of subjects: 62
Study: 11368983

Group type: EXPERIMENTAL
Intervention: Levonorgestrel (LNG) 0.75 mg administered twice immediately before ovulation
Number of subjects: 12
Study: 9412549

Group type: EXPERIMENTAL
Intervention: Inhaled albuterol (800 micrograms/day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 7528360

Group type: EXPERIMENTAL
Intervention: Low-dose aprotinin (30,000 KIU/kg in the priming solution)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no aprotinin)
Number of subjects: 30
Study: 3293777

Group type: EXPERIMENTAL
Intervention: Vitamin supplements (400 mg each of ascorbic acid and alpha-tocopherol)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Vitamin supplements
Number of subjects: 200
Study: 31804028

Group type: EXPERIMENTAL
Intervention: Long-pulsed Nd:YAG (1064 nm) laser
Number of subjects: 20

Group type: COMPARATOR
Intervention: Q-Switched Nd:YAG (1064 nm) laser
Number of subjects: 20
Study: 31253213

Group type: EXPERIMENTAL
Intervention: Nilotinib
Number of subjects: 80

Group type: COMPARATOR
Intervention: Imatinib
Number of subjects: 80
Study: 29072165

Group type: EXPERIMENTAL
Intervention: Standard care therapy for respiratory infection along with a single oral dose of 100,000 IU of vitamin D3
Number of subjects: 154

Group type: COMPARATOR
Intervention: Standard care therapy alone
Number of subjects: 154
Study: 29130267

Group type: EXPERIMENTAL
Intervention: Patient Navigator (PN) intervention with hospital visits and telephone outreach for 30 days post-discharge
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Overall cohort (Control)
Number of subjects: 0
Study: 24076011

Group type: EXPERIMENTAL
Intervention: 6-month home-based physical activity (PA) intervention
Number of subjects: 170

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 170
Study: 20828714

Group type: EXPERIMENTAL
Intervention: New hypotonic ORS containing zinc and prebiotics (group 2)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Standard hypotonic ORS (group 1)
Number of subjects: 119
Study: 19737278

Group type: EXPERIMENTAL
Intervention: Super-selective intraprostatic androgen deprivation therapy
Number of subjects: 6
Study: 17175104

Group type: EXPERIMENTAL
Intervention: 1000 mg acetaminophen
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: 50 mg rofecoxib (selective COX-2 inhibitor)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: 30 mg ketorolac (dual COX-1/COX-2 inhibitor)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study: 14996144

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg daily for up to 8 weeks
Number of subjects: 37
Study: 11977360

Group type: EXPERIMENTAL
Intervention: Topical treatment
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (22 healthy controls)
Number of subjects: 28
Study: 9046143

Group type: EXPERIMENTAL
Intervention: Dorsal approach
Number of subjects: 52

Group type: COMPARATOR
Intervention: Plantar approach
Number of subjects: 52
Study: 7935234

Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia (TIVA) with midazolam and fentanyl
Number of subjects: 13

Group type: COMPARATOR
Intervention: Inhalation anesthesia with thiamylal, enflurane, and nitrous oxide
Number of subjects: 13
Study: 3341258

Group type: EXPERIMENTAL
Intervention: Full-fat acidified milk fortified with 15 mg of elemental Fe as ferrous sulfate and 100 mg of ascorbic acid/100 g of powder
Number of subjects: 276

Group type: COMPARATOR
Intervention: Control group (milk without additives)
Number of subjects: 276
Study: 30379086

Group type: EXPERIMENTAL
Intervention: %predicted SVC
Number of subjects: 453

Group type: COMPARATOR
Intervention: Baseline SVC < median
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: Smaller declines in SVC over time
Number of subjects: 453
Study: 28025964

Group type: EXPERIMENTAL
Intervention: Test formulation of pregabalin 150-mg capsules
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reference formulation of pregabalin 150-mg capsules
Number of subjects: 0
Study: 24709775

Group type: EXPERIMENTAL
Intervention: Interferon alpha‐2b plus ribavirin
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Pegylated interferon alpha‐2a plus ribavirin
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control (healthy subjects)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Patients with complete early virological response (cEVR)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Patients with low TLR3 expressing CD14+ monocytes at baseline
Number of subjects: 70
Study: 23080548

Group type: EXPERIMENTAL
Intervention: Sequential clomiphene citrate/hMG regimen (CC/hMG)
Number of subjects: 90

Group type: COMPARATOR
Intervention: hMG regimen
Number of subjects: 90
Study: 20798427

Group type: EXPERIMENTAL
Intervention: Myofeedback-based teletreatment service
Number of subjects: 65

Group type: COMPARATOR
Intervention: Conventional care (Control)
Number of subjects: 65
Study: 19271419

Group type: EXPERIMENTAL
Intervention: MgCl2 5% solution (450 mg elemental magnesium)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Imipramine 50 mg daily
Number of subjects: 23
Study: 16649861

Group type: EXPERIMENTAL
Intervention: High self-esteem individuals
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Low self-esteem individuals
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Higher self-esteem
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Anxiously attached individuals
Number of subjects: 7
Study: 14602761

Group type: EXPERIMENTAL
Intervention: GH 25 microg/kg.d
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: GH 12.5 microg/kg.d
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 10744147

Group type: EXPERIMENTAL
Intervention: Clinical prediction rule with a score < or =4.0 and negative SimpliRED D-Dimer result
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Score <2.0 and negative D-Dimer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Score < or =4.0
Number of subjects: 0
Study: 8931521

Group type: EXPERIMENTAL
Intervention: Functional neuromuscular stimulation (FNS)
Number of subjects: 24
Study: 8123920

Group type: EXPERIMENTAL
Intervention: Early ECMO
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control (continued medical management)
Number of subjects: 41
Study: 3426184

Group type: EXPERIMENTAL
Intervention: IFN 6 MU/day
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: IFN 3 MU/day
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 29132879

Group type: EXPERIMENTAL
Intervention: Rivaroxaban (2.5 mg orally twice a day) plus Aspirin (100 mg once a day)
Number of subjects: 24824

Group type: EXPERIMENTAL
Intervention: Rivaroxaban (5 mg orally twice a day)
Number of subjects: 24824
Study: 25845277

Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg IV bolus at induction, followed by 0.25 mg/kg/h infusion until end of surgery)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 52
Study: 24117389

Group type: EXPERIMENTAL
Intervention: Ustekinumab 45 mg
Number of subjects: 545

Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg
Number of subjects: 545

Group type: COMPARATOR
Intervention: Placebo (initially) then Ustekinumab 45 mg or 90 mg
Number of subjects: 545
Study: 23561840

Group type: EXPERIMENTAL
Intervention: High-dose propofol (3.2 μg/mL)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Medium-dose propofol (2.4 μg/mL)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Low-dose propofol (1.8 μg/mL)
Number of subjects: 42
Study: 19092348

Group type: EXPERIMENTAL
Intervention: Celiac axis infusion (CAI) and radiotherapy (RT) consisting of intra-arterial mitoxantrone, 5-FU, leucovorin, and cisplatinum in combination with 30 x 1.8 Gy radiotherapy (group A)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Observation (group B)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Celiac axis infusion (CAI) and radiotherapy (RT) for periampullary tumors
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Celiac axis infusion (CAI) and radiotherapy (RT) for pancreatic cancer
Number of subjects: 120
Study: 16674623

Group type: EXPERIMENTAL
Intervention: Airtraq Laryngoscope
Number of subjects: 25

Group type: COMPARATOR
Intervention: Macintosh Laryngoscope
Number of subjects: 25
Study: 12500073

Group type: EXPERIMENTAL
Intervention: Paroxetine (20 or 40 mg)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Clomipramine (75 or 150 mg)
Number of subjects: 121
Study: 11303310

Group type: EXPERIMENTAL
Intervention: 100 ml of trometamol (TRIS, pH = 10.5) intravenously for 5 minutes, followed by deep breathing for 5 minutes at a rate of 40/min.
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 76
Study: 8623998

Group type: EXPERIMENTAL
Intervention: Neostigmine 0.06 mg.kg‐1
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Edrophonium 1 mg.kg‐1
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Butyrylcholinesterase (25 ml.kg‐1 and 70 ml.kg‐1 of human plasma equivalent)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control-TOF (group 1)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control-PTC (group 2)
Number of subjects: 87
Study: 1308025

Group type: EXPERIMENTAL
Intervention: Refractometric method
Number of subjects: 102

Group type: COMPARATOR
Intervention: Sulphosalycilic acid method
Number of subjects: 102

Group type: COMPARATOR
Intervention: Biuret method
Number of subjects: 102
Study: 3898847

Group type: EXPERIMENTAL
Intervention: Single preoperative intramuscular dose of cefoxitin (2 gm)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Two or three doses of cefoxitin (2 gm)
Number of subjects: 50
Study: 29220105

Group type: EXPERIMENTAL
Intervention: Selenium and coenzyme Q10 supplementation
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study: 26967693

Group type: EXPERIMENTAL
Intervention: Reinvitation letter and reminder sent 6 and 3 weeks before the new colonoscopy appointment date.
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Invitation to an educational meeting sent 6 weeks before the meeting date.
Number of subjects: 1000
Study: 24911368

Group type: EXPERIMENTAL
Intervention: Varenicline (n = 249)
Number of subjects: 498

Group type: COMPARATOR
Intervention: Placebo (n = 245)
Number of subjects: 498
Study: 22738801

Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg q.d.
Number of subjects: 870

Group type: COMPARATOR
Intervention: Sulfonylurea
Number of subjects: 870

Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 870
Study: 20410149

Group type: EXPERIMENTAL
Intervention: Rehabilitation exercise intervention over a 16-week period
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control group (healthy age-, gender-, and dwelling-matched individuals)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Weight transfer onto the affected leg during rehabilitation
Number of subjects: 91
Study: 19463340

Group type: EXPERIMENTAL
Intervention: Upfront thrombus aspiration
Number of subjects: 355

Group type: COMPARATOR
Intervention: Conventional primary PCI
Number of subjects: 355
Study: 15978268

Group type: EXPERIMENTAL
Intervention: Group 1 - acid+primer+adhesive
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Group 2 - only primer
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Group 3 - only bonding resin (light-cured for 10s)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Group 4 - only composite resin (light-cured for 40s)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Group 5 - calcium hydroxide
Number of subjects: 25
Study: 12024138

Group type: EXPERIMENTAL
Intervention: Endoscopic hemoclip placement
Number of subjects: 35

Group type: COMPARATOR
Intervention: Endoscopic epinephrine injection
Number of subjects: 35
Study: 10417603

Group type: EXPERIMENTAL
Intervention: medicolegal curriculum
Number of subjects: 64

Group type: COMPARATOR
Intervention: control group
Number of subjects: 64
Study: 7574325

Group type: EXPERIMENTAL
Intervention: Two-layer transversalis fascia repair
Number of subjects: 87

Group type: COMPARATOR
Intervention: Four-layer Shouldice repair
Number of subjects: 87
Study: 1675315

Group type: EXPERIMENTAL
Intervention: 150 mg/day aspirin
Number of subjects: 323

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 323
Study: 6447272

Group type: EXPERIMENTAL
Intervention: Mega-doses of vitamin E
Number of subjects: 1

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 1
Study: 30536496

Group type: EXPERIMENTAL
Intervention: Meditation
Number of subjects: 311

Group type: COMPARATOR
Intervention: Control
Number of subjects: 311
Study: 29085004

Group type: EXPERIMENTAL
Intervention: Submaximal exercise training
Number of subjects: 24
Study: 26353787

Group type: EXPERIMENTAL
Intervention: Written information provision about cancer related sexual changes (self-help condition; SH)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Written information accompanied by a single session of counselling (health professional condition; HP)
Number of subjects: 141
Study: 24283222

Group type: EXPERIMENTAL
Intervention: First- and second-generation antipsychotics
Number of subjects: 399
Study: 21338276

Group type: COMPARATOR
Intervention: Tetradecylthioacetic acid (TTA) 1000 mg daily for 28 days
Number of subjects: 0
Study: 19762678

Group type: EXPERIMENTAL
Intervention: Iowa Strengthening Families Program (ISFP)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 22
Study: 17519543

Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) given orally
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) in vitro
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Platelets from stroke patients
Number of subjects: 90

Group type: COMPARATOR
Intervention: Healthy control subjects (N=25)
Number of subjects: 90
Study: 15728132

Group type: EXPERIMENTAL
Intervention: Xenon as an anaesthetic
Number of subjects: 0
Study: 11498264

Group type: EXPERIMENTAL
Intervention: IL-1beta and IL-1ra polymorphisms in MS patients
Number of subjects: 98
Study: 9529766

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen treatment (100% oxygen, pressure)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (100% oxygen, no pressure)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 7994204

Group type: EXPERIMENTAL
Intervention: fibre-optic sensor
Number of subjects: 10

Group type: COMPARATOR
Intervention: mercury strain-gauge sensor
Number of subjects: 10
Study: 2690970

Group type: EXPERIMENTAL
Intervention: Systemic adjuvant therapy
Number of subjects: 0
Study: 769597

Group type: EXPERIMENTAL
Intervention: Intermittent assisted ventilation using the Retec breathing assistor
Number of subjects: 6
Study: 31786934

Group type: EXPERIMENTAL
Intervention: Ketamine (0.71 mg/kg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Midazolam (0.025 mg/kg)
Number of subjects: 40
Study: 30918134

Group type: EXPERIMENTAL
Intervention: Exenatide (10 μg b.i.d.) for 12 weeks
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Metformin (1,000 mg b.i.d.) for 12 weeks
Number of subjects: 182

Group type: COMPARATOR
Intervention: Control group (healthy women)
Number of subjects: 182
Study: 28343364

Group type: EXPERIMENTAL
Intervention: Morning aerobic exercise for 6 weeks
Number of subjects: 48

Group type: COMPARATOR
Intervention: Evening aerobic exercise for 6 weeks
Number of subjects: 48